Targeting β-arrestin2 in the treatment of l-DOPA–induced dyskinesia in Parkinson’s disease

Parkinson’s disease (PD) is characterized by severe locomotor deficits and is commonly treated with the dopamine (DA) precursor l-3,4-dihydroxyphenylalanine (l-DOPA), but its prolonged use causes dyskinesias referred to as l-DOPA–induced dyskinesias (LIDs). Recent studies in animal models of PD have...

Täydet tiedot

Tallennettuna:
Bibliografiset tiedot
Julkaisussa:Proc Natl Acad Sci U S A
Päätekijät: Urs, Nikhil M., Bido, Simone, Peterson, Sean M., Daigle, Tanya L., Bass, Caroline E., Gainetdinov, Raul R., Bezard, Erwan, Caron, Marc G.
Aineistotyyppi: Artigo
Kieli:Inglês
Julkaistu: National Academy of Sciences 2015
Aiheet:
PNAS Plus
Linkit:https://ncbi.nlm.nih.gov/pmc/articles/PMC4434696/
https://ncbi.nlm.nih.gov/pubmed/25918399
https://ncbi.nlm.nih.govhttp://dx.doi.org/10.1073/pnas.1502740112
Tagit: Lisää tagi
Ei tageja, Lisää ensimmäinen tagi!

Samankaltaisia teoksia